Serria, M., Hamza, E., Nosser, N., Zohdy, M., Hisham, F. (2022). Interleukin-23 and its Receptor Expression (IL-23R) in Psoriatic and Psoriatic Arthritis Patients. The Egyptian Journal of Hospital Medicine, 88(1), 2736-2741. doi: 10.21608/ejhm.2022.241130
Mohamed Saad Serria; Eman Hamza; Nessma A. Nosser; Marwa Zohdy; Fatma Azzahraa Hisham. "Interleukin-23 and its Receptor Expression (IL-23R) in Psoriatic and Psoriatic Arthritis Patients". The Egyptian Journal of Hospital Medicine, 88, 1, 2022, 2736-2741. doi: 10.21608/ejhm.2022.241130
Serria, M., Hamza, E., Nosser, N., Zohdy, M., Hisham, F. (2022). 'Interleukin-23 and its Receptor Expression (IL-23R) in Psoriatic and Psoriatic Arthritis Patients', The Egyptian Journal of Hospital Medicine, 88(1), pp. 2736-2741. doi: 10.21608/ejhm.2022.241130
Serria, M., Hamza, E., Nosser, N., Zohdy, M., Hisham, F. Interleukin-23 and its Receptor Expression (IL-23R) in Psoriatic and Psoriatic Arthritis Patients. The Egyptian Journal of Hospital Medicine, 2022; 88(1): 2736-2741. doi: 10.21608/ejhm.2022.241130
Interleukin-23 and its Receptor Expression (IL-23R) in Psoriatic and Psoriatic Arthritis Patients
Introduction: Psoriasis (Ps) is a systemic autoimmune disorder that develops under the influence of environmental factors in a genetically susceptible person. The IL-23/IL-17 axis is the primary signalling pathway for cellular and molecular alterations in Ps. Objective: The aim of the study was to investigate the levels of interleukin 23 (IL-23) in serum and its receptor expression (ILR23) in blood of patients with Ps and psoriatic arthritis (PsA), as well as to evaluate the possibility of using (IL23R) in blood as a marker for susceptibility of Psoriasis. Patients and Methods: Medical data and clinical evaluation were done and blood samples from patients and control groups were collected. Serum IL-23 concentration was measured using enzyme-linked immunosorbent assay (ELISA) and the Expression of IL-23R in human peripheral blood mononuclear cells (PBMCs) was determined using Western blotting. Results: Serum IL-23 concentration was significantly higher among Ps cases than in controls and it was significantly different between PsA and Ps groups. The protein expression of IL-23R was significantly greater in Ps group than in control group with no significant difference between Ps and PsA groups. Receiver operating characteristics (ROC) curve showed a diagnostic value for the increased blood IL-23R with a sensitivity of 83.3% and a specificity of 73.3% for psoriasis. Also, (ROC) curve showed a diagnostic value for the increased blood IL-23 with a sensitivity of 80% and a specificity of 73.3% for the diagnosis of psoriasis. Conclusion: Serum IL-23 and its receptor expression measurements are helpful tools in the diagnosis of Ps as well as in the prediction of PsA. We hypothesized that there is a link between IL-23 and IL-23R and the risk of Ps in addition to PsA, with evidence that the expression of IL-23R is linked to a significantly greater risk of psoriasis.